Backs FY25 revenue view 4.53B yen. Backs FY25 adjusted free cash flow view 750 yen-850 yen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Alkermes selling off on limited data disclosure, says BofA
- Takeda receives FDA clearance for HyHub, HyHub Duo
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
- Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton